300573 兴齐眼药
已收盘 10-31 15:00:00
资讯
新帖
简况
兴齐眼药(300573)发布向特定对象发行股票募集说明书,10月31日股价下跌3.73%
证券之星 · 10-31 09:18
兴齐眼药(300573)发布向特定对象发行股票募集说明书,10月31日股价下跌3.73%
兴齐眼药:暂未布局马来西亚和印尼市场
证券之星 · 10-31 01:09
兴齐眼药:暂未布局马来西亚和印尼市场
兴齐眼药:不同浓度硫酸阿托品滴眼液正处于审评阶段
证券之星 · 10-31 01:06
兴齐眼药:不同浓度硫酸阿托品滴眼液正处于审评阶段
股市必读:10月29日兴齐眼药发生1笔大宗交易 成交金额518.89万元
证券之星 · 10-29 17:09
股市必读:10月29日兴齐眼药发生1笔大宗交易 成交金额518.89万元
兴齐眼药(300573)9月30日股东户数5.41万户,较上期增加16.85%
证券之星 · 10-28
兴齐眼药(300573)9月30日股东户数5.41万户,较上期增加16.85%
兴齐眼药最新公告:第三季度净利润2.64亿元同比增长117.45%
证券之星 · 10-28
兴齐眼药最新公告:第三季度净利润2.64亿元同比增长117.45%
股市必读:兴齐眼药(300573)10月24日董秘有最新回复
证券之星 · 10-26
股市必读:兴齐眼药(300573)10月24日董秘有最新回复
兴齐眼药:公司会及时披露利润分配计划
证券之星 · 10-24
兴齐眼药:公司会及时披露利润分配计划
兴齐眼药(300573)披露完成工商变更登记公告,10月14日股价下跌3.75%
证券之星 · 10-14
兴齐眼药(300573)披露完成工商变更登记公告,10月14日股价下跌3.75%
兴齐眼药(300573.SZ):SQ-129玻璃体缓释注射液获得临床试验批准
智通财经 · 10-09
兴齐眼药(300573.SZ):SQ-129玻璃体缓释注射液获得临床试验批准
兴齐眼药:2025年第三季度报告预约披露时间为2025年10月29日
证券之星 · 09-26
兴齐眼药:2025年第三季度报告预约披露时间为2025年10月29日
兴齐眼药:构建线上线下一体化眼科慢病管理生态
证券之星 · 09-22
兴齐眼药:构建线上线下一体化眼科慢病管理生态
兴齐眼药:美欧品为国内首个获批近视防控眼用制剂
证券之星 · 09-18
兴齐眼药:美欧品为国内首个获批近视防控眼用制剂
兴齐眼药(300573)披露2025年半年度权益分派实施公告,9月16日股价上涨0.58%
证券之星 · 09-16
兴齐眼药(300573)披露2025年半年度权益分派实施公告,9月16日股价上涨0.58%
兴齐眼药:低浓度硫酸阿托品滴眼液通过多种途径综合防控近视的发生与发展
证券之星 · 09-16
兴齐眼药:低浓度硫酸阿托品滴眼液通过多种途径综合防控近视的发生与发展
股市必读:兴齐眼药(300573)9月12日董秘有最新回复
证券之星 · 09-14
股市必读:兴齐眼药(300573)9月12日董秘有最新回复
兴齐眼药:公司另外两种浓度的硫酸阿托品滴眼液(0.02%和 0.04%)已取得Ⅲ期临床试验总结报告
证券之星 · 09-11
兴齐眼药:公司另外两种浓度的硫酸阿托品滴眼液(0.02%和 0.04%)已取得Ⅲ期临床试验总结报告
股市必读:兴齐眼药(300573)9月9日董秘有最新回复
证券之星 · 09-09
股市必读:兴齐眼药(300573)9月9日董秘有最新回复
兴齐眼药:通过学术专题开展近视防控疾病教育,低浓度硫酸阿托品滴眼液已实现院内外广泛覆盖
市场资讯 · 09-09
兴齐眼药:通过学术专题开展近视防控疾病教育,低浓度硫酸阿托品滴眼液已实现院内外广泛覆盖
股市必读:兴齐眼药(300573)9月5日董秘有最新回复
证券之星 · 09-07
股市必读:兴齐眼药(300573)9月5日董秘有最新回复
加载更多
公司概况
公司名称:
沈阳兴齐眼药股份有限公司
所属行业:
医药制造业
上市日期:
2016-12-08
主营业务:
沈阳兴齐眼药股份有限公司的主营业务是眼科药物研发、生产、销售。公司的主要产品是眼科药物。公司先后荣获“辽宁省第九届省长质量奖银奖”、“辽宁五一劳动奖状”、“第十四届中国上市公司投资者关系天马奖”、第二十届“全国质量奖”、“国家级绿色工厂”、第十九届中国上市公司董事会金圆桌“优秀董事会”奖、中国上市公司协会“2024年度上市公司董办优秀实践案例”等奖项荣誉,并入选中国上市公司协会2024年上市公司可持续发展优秀实践案例,在眼科处方药物领域中处于优势地位。
发行价格:
5.16
{"stockData":{"symbol":"300573","market":"SZ","secType":"STK","nameCN":"兴齐眼药","latestPrice":80.21,"timestamp":1761894207000,"preClose":83.32,"halted":0,"volume":23035579,"delay":0,"changeRate":-0.0373,"floatShares":188000000,"shares":245000000,"eps":2.6339,"marketStatus":"已收盘","change":-3.11,"latestTime":"10-31 15:00:00","open":83.21,"high":83.84,"low":79.5,"amount":1869000000,"amplitude":0.0521,"askPrice":80.21,"askSize":100,"bidPrice":80.2,"bidSize":138,"shortable":0,"etf":0,"ttmEps":2.6339,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1762133400000},"marketStatusCode":5,"adr":0,"adjPreClose":83.32,"symbolType":"stock","openAndCloseTimeList":[[1761874200000,1761881400000],[1761886800000,1761894000000]],"highLimit":91.65,"lowLimit":74.99,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":245348945,"isCdr":false,"pbRate":11.01,"roa":"--","peRate":30.452941,"roe":"32.91%","epsLYR":1.94,"committee":-0.391685,"marketValue":19679000000,"turnoverRate":0.1222,"status":1,"floatMarketCap":15116000000},"requestUrl":"/m/hq/s/300573","defaultTab":"news","newsList":[{"id":"2579459686","title":"兴齐眼药(300573)发布向特定对象发行股票募集说明书,10月31日股价下跌3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579459686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579459686?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:18","pubTimestamp":1761902309,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,兴齐眼药报收于80.21元,较前一交易日下跌3.73%,最新总市值为196.79亿元。近日,沈阳兴齐眼药股份有限公司披露了《向特定对象发行股票募集说明书(申报稿)》。公告显示,公司拟向特定对象发行股票,募集资金总额不超过78,978.56万元,用于研发中心建设项目及补充流动资金。发行价格不低于定价基准日前20个交易日公司股票交易均价的80%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100035713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2579853164","title":"兴齐眼药:暂未布局马来西亚和印尼市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2579853164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579853164?lang=zh_cn&edition=full","pubTime":"2025-10-31 09:09","pubTimestamp":1761872955,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药(300573)10月31日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,公司2025 年第三季度(Q3):国外市场收入预计达 0.45 亿元(马来西亚 0.35 亿元 + 印尼 0.1 亿元),环比第二季度增长 16.7%。请问公司对海外市场的放量看待?未来海外市场是否会迎来暴增?兴齐眼药回复:尊敬的投资者您好,公司目前主营业务聚焦于国内市场,暂未布局您提及的马来西亚和印尼市场,具体业绩数据请您参考公司公开披露的定期报告。谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100013526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2579483092","title":"兴齐眼药:不同浓度硫酸阿托品滴眼液正处于审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2579483092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579483092?lang=zh_cn&edition=full","pubTime":"2025-10-31 09:06","pubTimestamp":1761872783,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药10月31日在投资者关系平台上答复投资者关心的问题。该浓度滴眼液和0.01%浓度市场规模是否更大?公司不同浓度硫酸阿托品滴眼液目前正处于审评阶段,后续达到信息披露标准时,公司将按照法律法规及相关规定,及时、准确地履行信息披露义务。不同浓度的硫酸阿托品滴眼液在临床使用过程中能够更好的满足不同近视人群对近视控制的需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100013448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0},{"id":"2579189446","title":"股市必读:10月29日兴齐眼药发生1笔大宗交易 成交金额518.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579189446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579189446?lang=zh_cn&edition=full","pubTime":"2025-10-30 01:09","pubTimestamp":1761757757,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘,兴齐眼药报收于82.01元,上涨5.29%,换手率16.42%,成交量30.94万手,成交额25.18亿元。当日关注点来自交易信息汇总:10月29日主力资金净流入9507.56万元,呈现明显吸筹迹象。交易信息汇总资金流向10月29日主力资金净流入9507.56万元;游资资金净流出5376.11万元;散户资金净流出4131.44万元。大宗交易10月29日兴齐眼药发生1笔大宗交易,成交金额518.89万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000001638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2578939765","title":"兴齐眼药(300573)9月30日股东户数5.41万户,较上期增加16.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578939765","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578939765?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:41","pubTimestamp":1761644476,"startTime":"0","endTime":"0","summary":"证券之星消息,近日兴齐眼药披露,截至2025年9月30日公司股东户数为5.41万户,较6月30日增加7809.0户,增幅为16.85%。在化学制药行业个股中,兴齐眼药股东户数高于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.38万户。从股价来看,2025年6月30日至2025年9月30日,兴齐眼药区间涨幅为28.27%,在此期间股东户数增加7809.0户,增幅为16.85%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800032286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2578935232","title":"兴齐眼药最新公告:第三季度净利润2.64亿元同比增长117.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578935232","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578935232?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:13","pubTimestamp":1761642786,"startTime":"0","endTime":"0","summary":"兴齐眼药(300573.SZ)发布2025年三季报,公司第三季度营业收入7.41亿元,同比增长35.34%;净利润2.64亿元,同比增长117.45%。2025年前三季度营业收入19.04亿元,同比增长32.27%;净利润5.99亿元,同比增长105.98%;基本每股收益2.44元。前三季度营业收入增长主要系报告期滴眼剂产品销售收入增加。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800030368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573"],"gpt_icon":0},{"id":"2578659946","title":"股市必读:兴齐眼药(300573)10月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2578659946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578659946?lang=zh_cn&edition=full","pubTime":"2025-10-27 01:47","pubTimestamp":1761500831,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,兴齐眼药报收于74.28元,上涨2.47%,换手率7.36%,成交量13.87万手,成交额10.28亿元。公司董事会将根据《公司章程》及相关法律法规要求,结合公司经营状况和财务状况,综合考虑后制定利润分配方案。若有相关计划,公司会及时披露。当日关注点来自交易信息汇总:10月24日主力资金净流入2647.29万元,显示主力对兴齐眼药的积极介入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2577255595","title":"兴齐眼药:公司会及时披露利润分配计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2577255595","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577255595?lang=zh_cn&edition=full","pubTime":"2025-10-24 16:48","pubTimestamp":1761295705,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药10月24日在投资者关系平台上答复投资者关心的问题。公司董事会将根据《公司章程》及相关法律法规要求,结合公司经营状况和财务状况,综合考虑后制定利润分配方案。若有相关计划,公司会及时披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400028945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2575211995","title":"兴齐眼药(300573)披露完成工商变更登记公告,10月14日股价下跌3.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575211995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575211995?lang=zh_cn&edition=full","pubTime":"2025-10-14 22:11","pubTimestamp":1760451075,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘,兴齐眼药报收于65.67元,较前一交易日下跌3.75%,最新总市值为161.12亿元。该股当日开盘68.23元,最高68.8元,最低65.37元,成交额达6.3亿元,换手率为4.98%。公司近日发布公告称,沈阳兴齐眼药股份有限公司已完成工商变更登记,并取得沈阳市浑南区市场监督管理局颁发的《营业执照》。相关变更事项已经公司第五届董事会第十次会议及2025年第二次临时股东大会审议通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400064990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2574861131","title":"兴齐眼药(300573.SZ):SQ-129玻璃体缓释注射液获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2574861131","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574861131?lang=zh_cn&edition=full","pubTime":"2025-10-09 16:22","pubTimestamp":1759998156,"startTime":"0","endTime":"0","summary":"智通财经APP讯,兴齐眼药 发布公告,近日,公司收到国家药品监督管理局签发的关于SQ-129玻璃体缓释注射液的《药物临床试验批准通知书》。根据化学药品2.2类改良型新药的有关要求,公司已经完成SQ-129玻璃体缓释注射液药学及非临床药理毒理学等多方面的研究,研究结果表明SQ-129玻璃体缓释注射液具有良好的安全性及临床开发价值。目前国内外尚无该产品获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兴齐眼药(300573.SZ):SQ-129玻璃体缓释注射液获得临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2570996005","title":"兴齐眼药:2025年第三季度报告预约披露时间为2025年10月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2570996005","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570996005?lang=zh_cn&edition=full","pubTime":"2025-09-26 16:57","pubTimestamp":1758877040,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药(300573)09月26日在投资者关系平台上答复投资者关心的问题。投资者提问:请问三季报披露时间是哪天?兴齐眼药回复:尊敬的投资者您好,公司2025年第三季度报告预约披露时间为2025年10月29日。谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600026485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2569027892","title":"兴齐眼药:构建线上线下一体化眼科慢病管理生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2569027892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569027892?lang=zh_cn&edition=full","pubTime":"2025-09-22 16:31","pubTimestamp":1758529883,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药09月22日在投资者关系平台上答复投资者关心的问题。公司旨在通过构建线上、线下一体化的眼科慢病管理生态,实现药品更广泛的可及性,推动各渠道协同增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200021039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300959","BK0231","300573"],"gpt_icon":0},{"id":"2568716384","title":"兴齐眼药:美欧品为国内首个获批近视防控眼用制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2568716384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568716384?lang=zh_cn&edition=full","pubTime":"2025-09-18 19:24","pubTimestamp":1758194646,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药09月18日在投资者关系平台上答复投资者关心的问题。公司另外两种浓度的硫酸阿托品滴眼液已取得Ⅲ期临床试验总结报告,未来这两款产品上市后,将进一步优化公司近视防控产品矩阵,持续为儿童青少年提供更全面的近视防控解决方案。截至目前该产品未被纳入集采范围,在市场竞争中仍保持价格稳定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091800032402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2567485454","title":"兴齐眼药(300573)披露2025年半年度权益分派实施公告,9月16日股价上涨0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567485454","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567485454?lang=zh_cn&edition=full","pubTime":"2025-09-16 22:12","pubTimestamp":1758031925,"startTime":"0","endTime":"0","summary":"截至2025年9月16日收盘,兴齐眼药报收于71.66元,较前一交易日上涨0.58%,最新总市值为175.82亿元。近日,公司发布《2025年半年度权益分派实施公告》。本次权益分派股权登记日为2025年9月23日,除权除息日为2025年9月24日。分红对象为截至股权登记日在中国结算深圳分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600037893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2567170127","title":"兴齐眼药:低浓度硫酸阿托品滴眼液通过多种途径综合防控近视的发生与发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2567170127","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567170127?lang=zh_cn&edition=full","pubTime":"2025-09-16 16:30","pubTimestamp":1758011447,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药09月16日在投资者关系平台上答复投资者关心的问题。目前尚无公开数据证明阿托品可以延缓中老年人群延缓眼睛老花进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600025695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2567154136","title":"股市必读:兴齐眼药(300573)9月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2567154136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567154136?lang=zh_cn&edition=full","pubTime":"2025-09-15 01:05","pubTimestamp":1757869516,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘,兴齐眼药报收于72.62元,上涨0.48%,换手率4.89%,成交量9.21万手,成交额6.65亿元。董秘最新回复投资者: 董秘您好!当日关注点来自交易信息汇总:9月12日主力资金净流出4731.85万元,散户资金净流入4495.13万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500000404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2566957137","title":"兴齐眼药:公司另外两种浓度的硫酸阿托品滴眼液(0.02%和 0.04%)已取得Ⅲ期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2566957137","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566957137?lang=zh_cn&edition=full","pubTime":"2025-09-11 16:03","pubTimestamp":1757577803,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药09月11日在投资者关系平台上答复投资者关心的问题。低浓度硫酸阿托品滴眼液需长期规范使用,患者将对产品的安全性、药物可及性及药事服务体系的要求进一步提高,具有近视防控产品矩阵协同效应的公司将更具优势。公司另外两种浓度的硫酸阿托品滴眼液已取得Ⅲ期临床试验总结报告,同时,基于近视发生发展过程中的基础研究结果,公司也在积极布局不同作用机制的近视防控产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100024009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2566617087","title":"股市必读:兴齐眼药(300573)9月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2566617087","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566617087?lang=zh_cn&edition=full","pubTime":"2025-09-10 02:59","pubTimestamp":1757444347,"startTime":"0","endTime":"0","summary":"截至2025年9月9日收盘,兴齐眼药报收于71.76元,下跌2.1%,换手率9.63%,成交量18.15万手,成交额13.35亿元。董秘: 尊敬的投资者您好,截至目前公司有多条生产线具备生产0.01%硫酸阿托品滴眼液的GMP资质,可以满足市场需求。公司将密切关注市场需求变化,及时做好产能安排。当日关注点来自交易信息汇总:9月9日主力资金净流出1227.9万元,散户资金净流入1841.33万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091000002400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2566662232","title":"兴齐眼药:通过学术专题开展近视防控疾病教育,低浓度硫酸阿托品滴眼液已实现院内外广泛覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2566662232","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566662232?lang=zh_cn&edition=full","pubTime":"2025-09-09 16:06","pubTimestamp":1757405203,"startTime":"0","endTime":"0","summary":"针对上述提问,兴齐眼药回应称:“尊敬的投资者您好,目前公司主要通过参与医药专业协会组织的眼健康学术专题,开展近视防控领域的疾病教育与品类教育工作;低浓度硫酸阿托品滴眼液目前已实现院内、院外渠道的广泛覆盖。未来,公司将持续推进全渠道的深度融合与协同发展,通过构建线上、线下一体化的眼科慢病管理生态,实现药品更广泛的可及性,推动各渠道协同增长。谢谢。”","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/09160653019153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2565524550","title":"股市必读:兴齐眼药(300573)9月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2565524550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565524550?lang=zh_cn&edition=full","pubTime":"2025-09-08 02:32","pubTimestamp":1757269934,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘,兴齐眼药报收于72.05元,上涨1.19%,换手率9.57%,成交量18.03万手,成交额12.92亿元。董秘最新回复投资者: 请问目前股东人数多少?交易信息汇总资金流向9月5日主力资金净流出1202.08万元;游资资金净流入4814.05万元;散户资金净流出3611.97万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800000677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1761975250607,"stockEarnings":[{"period":"1week","weight":0.0798},{"period":"1month","weight":0.2203},{"period":"3month","weight":0.3129},{"period":"6month","weight":0.4308},{"period":"1year","weight":0.3185},{"period":"ytd","weight":0.6472}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0185},{"period":"3month","weight":0.1109},{"period":"6month","weight":0.2061},{"period":"1year","weight":0.2058},{"period":"ytd","weight":0.1799}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"沈阳兴齐眼药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54149人(较上一季度增加16.85%)","perCapita":"3480股","listingDate":"2016-12-08","address":"辽宁省沈阳市浑南区中国(辽宁)自由贸易试验区沈阳片区新运河路25号","registeredCapital":"24534万元","survey":" 沈阳兴齐眼药股份有限公司的主营业务是眼科药物研发、生产、销售。公司的主要产品是眼科药物。公司先后荣获“辽宁省第九届省长质量奖银奖”、“辽宁五一劳动奖状”、“第十四届中国上市公司投资者关系天马奖”、第二十届“全国质量奖”、“国家级绿色工厂”、第十九届中国上市公司董事会金圆桌“优秀董事会”奖、中国上市公司协会“2024年度上市公司董办优秀实践案例”等奖项荣誉,并入选中国上市公司协会2024年上市公司可持续发展优秀实践案例,在眼科处方药物领域中处于优势地位。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兴齐眼药,300573,兴齐眼药股票,兴齐眼药股票老虎,兴齐眼药股票老虎国际,兴齐眼药行情,兴齐眼药股票行情,兴齐眼药股价,兴齐眼药股市,兴齐眼药股票价格,兴齐眼药股票交易,兴齐眼药股票购买,兴齐眼药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}